Atezolizumab–bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial. // JHEP Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2589555926002739?dgcid=rss_sd_all
Atezolizumab–bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial. JHEP Reports. https://www.sciencedirect.com/science/article/pii/S2589555926002739?dgcid=rss_sd_all
“Atezolizumab–bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial.” JHEP Reports.
@article{article89717,
title = {Atezolizumab–bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial},
journal = {JHEP Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2589555926002739?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...